Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 17, 2017
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2017 UBS Global Healthcare Conference on Tuesday, May 23, 2017 in New York City. Susie Lisa, vice president, investor...
-
May 16, 2017
Boston Scientific (NYSE: BSX) today announced positive results from the REPRISE III clinical trial, presented at the annual EuroPCR Scientific Program, in Paris. Data from the study demonstrated...
-
May 16, 2017Acquisition Expands Company's Structural Heart Portfolio; Increases Offerings for the Treatment of Patients with Valvular Heart Disease
Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Symetis SA, a privately-held Swiss structural heart company focused on minimally-invasive transcatheter...
-
May 12, 2017Largest Prospective Study of the WATCHMAN Device Presented as Late-Breaking Trial at Heart Rhythm 2017
Boston Scientific (NYSE: BSX) today announced positive safety and efficacy rates of the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device from the EWOLUTION registry presented during a...
-
May 12, 2017Analyses Evaluated the Impact of Ethnicity, Gender and Income on Cardiovascular Outcomes
New analyses from the Boston Scientific Corporation (NYSE: BSX) sponsored PLATINUM Diversity study underscore the need for greater understanding of the clinical and nonclinical barriers that can...
-
May 11, 2017Late-Breaker Data Presented at Heart Rhythm 2017
Boston Scientific (NYSE: BSX) today announced results from the U.S. post-market approval study evaluating 'real-world' patients implanted with the Subcutaneous Implantable Defibrillator (S-ICD)...
-
May 10, 2017Pivotal Data From REPRISE III and EWOLUTION Among Four Late-breaking Clinical Trials to be Presented
Boston Scientific (NYSE: BSX) today announced the schedule of key data presentations, including four late-breaking clinical trials, that will be featured at the annual EuroPCR Scientific Program,...
-
May 9, 2017New Devices Combine Longest-Lasting Battery Technology, Therapy Optimization and HeartLogic™ Heart Failure Diagnostics
Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the Resonate™ family of implantable cardioverter defibrillator (ICD) and cardiac resynchronization...
-
May 3, 2017Late-Breaking Clinical Trials Feature Subcutaneous Implantable Defibrillator and WATCHMAN™ Left Atrial Appendage Closure Device
Boston Scientific (NYSE: BSX) today announced the schedule of key data presentations, including two late-breaking clinical trials, that will be featured at the 38th Annual Scientific Sessions of...
-
May 1, 2017
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Bank of America Merrill Lynch 2017 Healthcare Conference on Thursday, May 18, 2017 in Las Vegas. Susie Lisa, vice...